ROTTAPHARM
🇫🇷France
Clinical Trials
9
Active:1
Completed:4
Trial Phases
3 Phases
Phase 2:3
Phase 3:2
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (37.5%)Phase 2
3 (37.5%)Phase 3
2 (25.0%)Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome
Not Applicable
Completed
- Conditions
- Metabolic SyndromeInsulin-resistanceLeft Ventricular Hypertrophy
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 159
- Registration Number
- NCT02295176
- Locations
- 🇮🇹
Domenico Bonaduce, Naples, Italy
🇮🇹Ferruccio Galletti, Naples, Italy
🇮🇹Giuseppe Schillaci, Terni, Italy
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Phase 2
Withdrawn
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Rottapharm
- Registration Number
- NCT01871662
- Locations
- 🇪🇬
Al-Manial University Hospital, Kasr El-Aini Faculty Medicine, Cairo University, Cairo, Egypt
Estromineral Serena Plus and Symptomatic Menopause
Not Applicable
- Conditions
- Menopause
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 300
- Registration Number
- NCT01730989
- Locations
- 🇮🇹
Siena University, Siena, Italy
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Phase 2
Terminated
- Conditions
- HCV Recurrence After Liver Transplantation
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 14
- Registration Number
- NCT01535092
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Phase 2
Terminated
- Conditions
- Hepatitis C Virus Recurrence
- Interventions
- Drug: Saline
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 20
- Registration Number
- NCT01518933
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy
- Prev
- 1
- 2
- Next
News
No news found